Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& onset

: HbA1c effect at 12-16 weeks (slower than other classes)

or ~30 min

Use the filters below to narrow your results.

Belsomra (1) · Dayvigo (1) · Quviviq (1)

Dual orexin receptor antagonist (DORA) (3) · the first approved (1)

None (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1)

Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1)

10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1)

25 mg, 50 mg tablets (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)

10 mg/d (1) · 20 mg/d (1) · 50 mg/d (1)

Oral (3)

~12 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

~44% (1) · ~62% (1) · ~82% (1)

Limited data; avoid (3)

Rx, Schedule IV (US) (3)

Error: operator for the virtual field 'Medicines.classes' must be 'HOLDS', 'HOLDS NOT', 'HOLDS LIKE' or 'HOLDS NOT LIKE'.

There are no results for this report.

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"